Heart and Blood Diseases

All Conditions

Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Symptoms and General Pathology

Rare Diseases

Thrombosis

Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Prostatic Neoplasms

Body Weight

Lung Neoplasms

Disease Progression

Venous Thrombosis

Embolism

Embolism and Thrombosis

Vascular Diseases

Pancreatic Cancer

Fibrinolytic Agents

Anticoagulants

All Drugs and Chemicals

Gastrointestinal Agents

Heparin

Calcium heparin

Heparin, Low-Molecular-Weight

Tinzaparin

Dalteparin

Pancrelipase

Nadroparin

Pancreatin

Patients will receive all standard anticancer treatment. Patients in this arm will not receive nadroparin

Patients will be randomized to receive standard anticancer treatment. Nadroparin patients will be treated with therapeutic doses of subcutaneous (s.c). nadroparin for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2-week periods of therapeutic doses of nadroparin will be given for a total of 6 cycles each separated by a 4-week wash-out. The study treatment period ends at week 46 regardless of number of cycles achieved at that moment.

Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.

GSK Clinical Trials

This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

GlaxoSmithKline

Thromboembolism

Venous Thromboembolism

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Nadroparin, 0.4mL, subcutaneously, qid, given by long-term

Nadroparin, 0.4mL, subcutaneously, qid, given during hospitalization

Nadroparin, long term

Nadroparin: short-term

Shengqing Li, MD, PhD

Zhihua Ruan, MD

Wei Xiong, MD

Xueqin Yang, MD

Qi Zhou, MD

Guifang Zhang, MD

Zhifen Luo, MD

Yanqiu Zhao, MD

Yanwei Guo, MD

Jie Li, MD

Fengyun Wang, MD

Cuiying Zhang, MD

Mei Yin, MD

Zhengxia Wu, MD

Zhangqin Chen, MD

Manxiang Li, MD, PhD

Yonghong Xie, MD, PhD

Xuemin Yang, MD

Yu Yao, MD

Hong Zhao, MD

Xiang Song, MD

Ping Yu, MD

Haitao Lan, MD

Yiming Reheman, MD

Kegang Jiao, MD

To compare the efficacy and safety of prophylaxis of venous thromboembolism by Nadroparin during hospitalization to long-term usage in patients with advanced lung cancer treated by chemotherapy and/or radiotherapy.

This is a prospective, multi-center, randomized and controlled study. Advanced lung cancer patients without venous thromboembolism(VTE) are included. The selected patients were randomized into A and B groups. Group A: Nadroparin given during hospitalization, 0.4mL, subcutaneously, qid; Group B: Nadroparin given by long-term, 0.4mL, subcutaneously, qid. The incidence of VTE , the risks of bleeding and overall survival in two groups of patients are studied at different time points.

Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer

Phase Ⅲ Study of Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer by Nadroparin

Shengqing Li

Consultant, Associate professor

Carcinoma

Adenocarcinoma

Carcinoma, Hepatocellular

Liver Diseases

Liver Neoplasms

Gastrointestinal Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Antineoplastic Agents

Hematinics

Carboplatin

Fluorouracil

Chlorotrianisene

Liver Extracts

Ethiodized Oil

50 HCC patients will be allocated to receive Nadroparin 4100 AXa iu twice daily 3 days after TACE which lasted for 6 weeks

50 HCC patients randomly assigned to receive TACE without LMWH

Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks

LMWH

transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。

TACE

Shen Feng, MD

Hepatocellular carcinoma (HCC) is a major tumor type worldwide, especially in China as the sequence of hepatitis B and liver cirrhosis. Activation of the coagulation system occurs commonly in patients with malignancy. Several studies have suggested that anticoagulant therapy may improve survival in patients with malignancy. The low molecular weight heparins (LMWHs) lend themselves to such studies because of their effects in experimental models of malignancy and the relative ease of administration compared with unfractionated heparin. The purpose of the present RCT was to determine whether addition of LMWH to transarterial chemoembolization (TACE) would improve HCC patient outcome compared with TACE alone.

100 patients will be randomly assigned to receive either TACE alone or TACE plus LMWH. A block of every 4 participants and a stratified randomization according to portal vein cancer emboli will be used to restrict randomization. LMWH consisted of nadroparin Ca will be given at a dose of 4100 U twice daily during 6 weeks after TACE. The time to progression(TTP) and overall survival within two years will be used to evaluate the effect of LMWH on HCC.

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

A Clinical Randomized Control Trial of Combination TACE With and Without Low-molecular-weight Heparin in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

vice president of the Eastern Hepatobiliary Surgery Hospotal

nadroparin

Catherine Weber, MD

To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care

Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care

University Hospital, Geneva

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer	NCT00312013	Thrombosis, Ven...	Nadroparin	18 Years -	GlaxoSmithKline
Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer	NCT01980849	Lung Cancer	Nadroparin, lon... Nadroparin: sho...	18 Years - 75 Years	Air Force Military Medical University, China
The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma	NCT00827554	Hepatocellular ...	LMWH TACE	18 Years - 75 Years	Eastern Hepatobiliary Surgery Hospital
The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma	NCT00827554	Hepatocellular ...	LMWH TACE	18 Years - 75 Years	Eastern Hepatobiliary Surgery Hospital
Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care	NCT00303407	Cancer Venous Thromboe...	nadroparin	0 Years -	University Hospital, Geneva
Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer	NCT01980849	Lung Cancer	Nadroparin, lon... Nadroparin: sho...	18 Years - 75 Years	Air Force Military Medical University, China

Spots Global Cancer Trial Database for nadroparin

Every month we try and update this database with for nadroparin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for nadroparin

Every month we try and update this database with for nadroparin cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for nadroparin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.